Moreover significant upregulation of CDK5 expression has been reported in colorectal, head/neck, breast, lung, ovarian, lymphoma, prostate, sarcoma, myeloma and bladder cancers, and there is well documented evidence that it plays a role in these cancers as well as lymphoma and multiple myeloma [180,181,182,183,184,185,258,259,260]. Here, CDK5 is linked to AL amyloidosis.